NurExone Biologic (TSXV:NRX) FCF Margin % : 0.00% (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is NurExone Biologic FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. NurExone Biologic's Free Cash Flow for the three months ended in Sep. 2024 was C$-1.52 Mil. NurExone Biologic's Revenue for the three months ended in Sep. 2024 was C$0.00 Mil. Therefore, NurExone Biologic's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.

As of today, NurExone Biologic's current FCF Yield % is -12.52%.

The historical rank and industry rank for NurExone Biologic's FCF Margin % or its related term are showing as below:

TSXV:NRX's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -140.87
* Ranked among companies with meaningful FCF Margin % only.

NurExone Biologic FCF Margin % Historical Data

The historical data trend for NurExone Biologic's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NurExone Biologic FCF Margin % Chart

NurExone Biologic Annual Data

Trend

Dec21

Dec22

Dec23

FCF Margin %

NurExone Biologic Quarterly Data
	Mar21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial									-	-	-	-	-

Competitive Comparison of NurExone Biologic's FCF Margin %

For the Biotechnology subindustry, NurExone Biologic's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NurExone Biologic's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NurExone Biologic's FCF Margin % distribution charts can be found below:

* The bar in red indicates where NurExone Biologic's FCF Margin % falls into.

Save Embed

;

Save Embed

;

NurExone Biologic FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

NurExone Biologic's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-4.107	/	0
	=	%

NurExone Biologic's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-1.516	/	0
	=	%

NurExone Biologic FCF Margin % Related Terms

Thank you for viewing the detailed overview of NurExone Biologic's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

NurExone Biologic Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (TSXV:NRX) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

NRXBF:USA J90:Germany

Address

1 Adelaide St. East, Suite 801, Toronto, ON, CAN, M5C 2V9

Website

https://www.nurexone.com

NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.

Executives

James Angus Wilson (bilkstys-) Richardson

10% Security Holder, Director, Senior Officer

NurExone Biologic Headlines

No Headlines